» Articles » PMID: 14749160

Antihistone and Anti-double-stranded Deoxyribonucleic Acid Antibodies Are Associated with Renal Disease in Systemic Lupus Erythematosus

Overview
Journal Am J Med
Specialty General Medicine
Date 2004 Jan 30
PMID 14749160
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We sought to assess the nephritogenic antibody profile of patients with systemic lupus erythematosus (SLE), and to determine which antibodies were most useful in identifying patients at risk of nephritis.

Methods: We studied 199 patients with SLE, 78 of whom had lupus nephritis. We assayed serum samples for antibodies against chromatin components (double-stranded deoxyribonucleic acid [dsDNA], nucleosome, and histone), C1q, basement membrane components (laminin, fibronectin, and type IV collagen), ribonucleoprotein, and phospholipids. Correlations of these antibodies with disease activity (SLE Disease Activity Index) and nephropathy were assessed. Patients with no initial evidence of nephropathy were followed prospectively for 6 years.

Results: Antibodies against dsDNA, nucleosomes, histone, C1q, and basement membrane components were associated with disease activity (P <0.05). In a multivariate analysis, anti-dsDNA antibodies (odds ratio [OR] = 6; 95% confidence interval [CI]: 2 to 24) and antihistone antibodies (OR = 9.4; 95% CI: 4 to 26) were associated with the presence of proliferative glomerulonephritis. In the prospective study, 7 (6%) of the 121 patients developed proliferative lupus glomerulonephritis after a mean of 6 years of follow-up. Patients with initial antihistone (26% [5/19] vs. 2% [2/95], P = 0.0004) and anti-dsDNA reactivity (6% [2/33] vs. 0% [0/67], P = 0.048) had a greater risk of developing proliferative glomerulonephritis than patients without these autoantibodies.

Conclusion: In addition to routine anti-dsDNA antibody assay, antihistone antibody measurement may be useful for identifying patients at increased risk of proliferative glomerulonephritis.

Citing Articles

Clinical Profile and Outcomes of Patients With Systemic Lupus Erythematosus.

Bagare P, Borle A, Baluni P, Ekbote G, Sangale S Cureus. 2024; 16(9):e68541.

PMID: 39364459 PMC: 11448960. DOI: 10.7759/cureus.68541.


Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells.

Sole C, Royo M, Sandoval S, Moline T, Gabaldon A, Cortes-Hernandez J Int J Mol Sci. 2024; 25(8).

PMID: 38673811 PMC: 11050013. DOI: 10.3390/ijms25084226.


Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.


Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study.

Hsu T, Yang Y, Wang L, Lee J, Yu H, Lin Y Pediatr Rheumatol Online J. 2023; 21(1):28.

PMID: 36964531 PMC: 10039593. DOI: 10.1186/s12969-023-00806-x.


Significance of co-positivity for anti-dsDNA, -nucleosome, and -histone antibodies in patients with lupus nephritis.

Choi S, Park D, Kang J, Lee S Ann Med. 2023; 55(1):1009-1017.

PMID: 36896834 PMC: 10795605. DOI: 10.1080/07853890.2023.2187076.